Reference is made to the stock exchange notice dated 3 November 2010 and the prospectus dated 2 November 2010 regarding a subsequent offering of up to 60,000,000 offer shares in DiaGenic ASA (“DiaGenic” or the “Company”), each with a nominal value of NOK 0.05, at a subscription price of NOK 0.50 per share with subscription rights for shareholders of the Company as of 6 October 2010, except shareholders who were allocated shares in the private placement completed on 6 October 2010.

The subscription period in the subsequent offering in DiaGenic expired at 17:30 (CET) on 17 November 2010. At the end of the subscription period, DiaGenic had received subscriptions for a total of 94,406,689 new shares. Consequently, the subsequent offering was oversubscribed by approximately 57.3 per cent.

Approximately 50.9 per cent of the subscribed new shares (approximately 48.0 million shares) were subscribed by exercising subscription rights. Approximately 49.1per cent of the subscribed new shares (approximately 46.4 million shares) were subscribed for through oversubscription by holders of subscription rights or by subscribers without subscription rights.

In a board meeting 23 November 2010, the Board of Directors of DiaGenic approved the final allocation of the shares offered in the subsequent offering based on the allocation criteria set out in the prospectus dated 2 November 2010. A total of 60,000,000 new shares have been allocated. Approximately 48.0 million new shares have been allocated to subscribers on the basis of exercised subscription rights. Approximately 12.0 million new shares have been allocated to holders of subscription rights on basis of oversubscription. No allocation has been made to subscribers without subscription rights.

Letters of notification of new shares allocated and the corresponding subscription amount to be paid by each subscriber are expected to be distributed on 23 November 2010. Payment for the allocated shares falls due on 26 November 2010 in accordance with the payment procedures described in the prospectus.

The new shares may not be transferred or traded before they are fully paid and the share capital increase pertaining to the subsequent offering has been registered with the Norwegian Register of Business Enterprises. It is expected that the share capital increase will be registered in the Norwegian Register of Business Enterprises on or about 6 December 2010 and that the new shares will be admitted to trading on the Oslo Stock Exchange on the same day.

Through the subsequent offering, DiaGenic will receive proceeds of NOK 30,000,000 before the deduction of transaction costs. Following registration of the share capital increase in the Norwegian Register of Business Enterprises, the Company's share capital will be NOK 13,511,826 divided into 270,236,520 shares, each with a nominal value of NOK 0.05.

DnB NOR Markets acted as manager in the subsequent offering.


Erik Christensen, CEO

Telephone: 47 95939918


About DiaGenic ASA

DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts of the body. DiaGenic has developed and CE marked two blood based diagnostic tests, BCtect® for early breast cancer detection and ADtect® for early detection of Alzheimer’s Disease. The company protects its technology through an extensive patent portfolio. DiaGenic promotes its products towards leading pharmaceutical and imaging companies, and towards clinicians. DiaGenic is listed on the Oslo Stock Exchange. For more information visit

About Us

NEL ASA is a leading global supplier of hydrogen technology for industrial / energy purposes, and has made over 500 deliveries in more than 50 countries. The company's main products are hydrogen production plants based on water electrolysis, complete hydrogen stations for transport and renewable energy storage solutions. The company has its roots from the hydrogen activities of Norsk Hydro, which dates back to 1927. The company also has a number of patents related to tests for early detection and diagnosis of diseases.